



## XTL Biopharmaceuticals to Present at the Jefferies Life Sciences Conference

**New York, NY, June 26, 2006** – XTL Biopharmaceuticals, Ltd. (Nasdaq: XTLB, LSE: XTL;TASE:XTL) announced today that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Jefferies Life Sciences Conference. Mr. Bentsur's presentation will take place on Wednesday, June 28, 2006 at 10:45 am EDT at The Mandarin Oriental Hotel in New York City.

A live audio webcast of Mr. Bentsur's presentation will be available at <http://www.wsw.com/webcast/jeff11/xtlb/>. An archived version of the webcast will be available following the conclusion of the live presentation.

### **About XTL Biopharmaceuticals, Ltd.**

XTL Biopharmaceuticals Ltd. ("XTLbio") is engaged in the acquisition, development and commercialization of therapeutics for the treatment of infectious diseases, with a focus on hepatitis C. XTLbio is developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is currently in a Phase 1 clinical trial in chronic hepatitis C patients. XTLbio is also developing XTL-6865 - a combination of two monoclonal antibodies against the hepatitis C virus - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTLbio's hepatitis C pipeline also includes several families of pre-clinical hepatitis C small molecule inhibitors. In addition, XTLbio has out-licensed to Cubist Pharmaceuticals an antibody therapeutic against hepatitis B, HepeX-B, which has recently completed a Phase 2b clinical study in hepatitis B liver transplant patients. XTLbio is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

### **Contact:**

Ron Bentsur  
Chief Executive Officer  
(212) 531-5971  
[rbentsur@xtlbio.com](mailto:rbentsur@xtlbio.com)